DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPPOS)

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 糖尿病预防计划（DPP）是一项多中心对照临床试验，旨在检查强化生活方式干预或美托洛尔在因存在糖耐量异常（IGT）而被选为高风险人群中预防或延迟糖尿病发展的疗效。根据1997年ADA标准定义的糖尿病发展是主要结局，而心血管疾病及其危险因素是重要的次要结局。 与安慰剂治疗组相比，生活方式干预组和二甲双胍治疗组的糖尿病发生率在统计学上显著降低且具有临床意义（风险分别降低58%和31%），因此DPP数据监测委员会和NIDDK于2001年8月结束了研究的设盲治疗期，比原计划提前一年。 DPP解决了其主要目标，确定了生活方式改变和二甲双胍在降低高风险种族多样性人群中糖尿病发病率方面的有效性，平均持续2.8年;然而，许多重要问题仍未得到解答。 糖尿病预防计划结局研究（DPPOS）是一项前瞻性研究，旨在研究DPP干预对持续预防或延迟糖尿病以及预防或改善其并发症（特别是心血管疾病和糖尿病微血管病）的影响。总体设计的基本原理是维持DPP中有效的治疗，以评估对糖尿病预防和并发症的长期影响。 所有受试者将接受5年随访，从DPP开始后平均随访约9年。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of an intensive lifestyle intervention or Metformin to prevent or delay the development of diabetes in a population selected to be at high risk due to the presence of impaired glucose intolerance (IGT). Development of diabetes, defined by the 1997 ADA criteria, was the primary outcome while cardiovascular disease and its risk factors were important secondary outcomes. On the basis of a statistically significant and clinically compelling decrease in the development of diabetes in the lifestyle intervention and the Metformin treated groups (58% and 31% reduction in hazards respectively) compared with the placebo treated group the DPP Data Monitoring Board and NIDDK ended the masked treatment phase of the study August 2001, one year earlier than originally planned. The DPP addressed its primary objective, establishing the efficacy of lifestyle modification and Metformin in decreasing the incidence of diabetes in an ethnically diverse population at high risk for an average of 2.8 years; however, many important issues remained unanswered. The Diabetes Prevention Program Outcomes Study (DPPOS) is a prospective study of the effects of DPP interventions on continued prevention or delay of diabetes, and on preventing or ameliorating its complications, specifically cardiovascular disease and diabetic microangiopathy. The rationale for the overall design is to provide maintenance of therapies found to be effective in DPP, to assess the long-term impacts on diabetes prevention and complications. All participants will be followed for five years, with a total mean follow-up of approximately 9 years from the beginning of DPP.